33-505 : Special Drug Use-Results Survey of OPDIVO

JRCT ID: jRCT2031240473

Registered date:08/11/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Recurrent or Refractory Classical Hodgkin Lymphoma
• Date of first enrollment: 27/09/2021
• Target sample size: 20
• Study type: Observational

Outcome(s)

Primary Outcome

'[Safety]
a) Occurrence status of adverse drug reactions and infections
b) Adverse events

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: < 15age old
• Gender: Both
• Include criteria: Pediatric patients with recurrent or refractory classical hodgkin lymphoma, who have recieved OPDIVO for the first time
• Exclude criteria: 'Patients who have received OPDIVO previously

Related Information

• Primary Sponsor: Kuro Toshihiko